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Observational studies indicate that vaccine-induced immunity can decline over time. However, few researchers have incorporated
this kind of waning effect into their virus spread models. In this study, we simulate an inﬂuenza epidemic that considers the effects of
waning immunity by ﬁtting epidemiological models to CDC secondary historical data aggregated on a weekly basis, and derive the
transmission rates at which susceptible individuals become infected over the course of the inﬂuenza season. Using a system of
differential equations, we deﬁne four groups of individuals in a population: susceptible, vaccinated, infected, and recovered. We show
that a larger number of initially infected individuals might not only bring the inﬂuenza season to an end sooner but also reduce the
epidemic size. Moreover, any inﬂuenza virus that entails a faster recovery rate does not necessarily lead to a smaller epidemic size. We
illustrate how simulation helps in understanding the effects of inﬂuenza epidemiological model in the presence of waning inﬂuenza
vaccine immunity.
Abbreviations: CDC = Centers for Disease Control and Prevention, SIR = Susceptible-Infectious-Recovered, SVIR =
Susceptible, vaccinated, infectious, recovered.
Keywords: inﬂuenza, simulation, vaccine, waning immunity

to CDC the total number of respiratory specimens tested and the
number that tested positive for inﬂuenza viruses.
Recently, researchers have started to thoroughly investigate
and give special attention to the waning effectiveness of
vaccination-induced immunity in the human body. In the 2017
to 2018 inﬂuenza season, there were as many as 50 viruses
identiﬁed for vaccine productions.[3] Given the selected viruses
for the new formulation, vaccine manufacturers are racing
against time as they produce, test, and distribute the vaccine
under a tight schedule.[3–5] Unfortunately, antigenically variable
pathogens, such as inﬂuenza viruses, are living organisms and are
capable of continuously altering the proteins or carbohydrates on
their surface and mutating to different strains, thereby potentially
escaping from the immunity induced by vaccination.[6] Many
studies have reported that vaccine effectiveness within a single
inﬂuenza season can decrease over time. Kissling et al[7] stated
that the decreasing inﬂuenza vaccine effectiveness could be the
result of virus changes through the season or waning immunity.
Pebody et al[8] and Belongia et al[9] advocated the need for
developing inﬂuenza vaccines that provide better and longerlasting protection in view of the occurrence of late past-season
outbreaks. Hill et al[10] developed a multi-strain transmission
model to predict the chronological interactions between the
inﬂuenza viruses and waning immunity among the population.
In this study, we aim to update classic epidemiological models
by explicitly accounting for waning vaccine immunity over time,
as well as to examine the effects that various parameters have on
the size of the inﬂuenza epidemic. Methodologically, we employ
simulation, which has been one common approach for
understanding the course of an inﬂuenza epidemic both in
practice and in the literature.[11,12] Goeyvaerts et al[13] developed
a seasonal inﬂuenza transmission model for evaluating the impact
of vaccination on the incidence of infection, disease, and
mortality. The authors proposed to directly estimate the values
of the seasonal inﬂuenza model parameters by ﬁtting the model to

1. Introduction
Inﬂuenza is a contagious disease around the world. Year after
year, inﬂuenza viruses cause illness to people of all ages, which
can lead to inﬂuenza-related complications or even trigger more
severe inﬂammation in the body. In fact, inﬂuenza has been
ranked as the eighth leading cause of death in 2017.[1] According
to the World Health Organization,[2] annual inﬂuenza-related
death tolls ranged from 290,000 to 650,000 worldwide. Since
1997, the Centers for Disease Control and Prevention (CDC)
have been tracking inﬂuenza activity and inﬂuenza-related
illnesses. In the United States, CDC produces inﬂuenza surveillance data, such as the percentage of specimens testing positive
for an inﬂuenza virus. Every week, all clinical laboratories report
Editor: Antonio Palazón-Bru.
This research was supported in part by a research grant from Bucknell
University’s Freeman College of Management.
The authors have no conﬂicts of interest to disclose.
The datasets generated during and/or analyzed during the current study are
available from the corresponding author on reasonable request.
Department of Analytics and Operations Management Bucknell University,
Lewisburg, PA.
∗

Correspondence: Chun-Miin (Jimmy) Chen, Department of Analytics and
Operations Management, Bucknell University, Lewisburg, PA 17837
(e-mail: jimmy.chen@bucknell.edu).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative
Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is
permissible to download, share, remix, transform, and buildup the work provided
it is properly cited. The work cannot be used commercially without permission
from the journal.
How to cite this article: Chen CM, Stanciu AC. Simulating inﬂuenza epidemics
with waning vaccine immunity. Medicine 2021;100:36(e27169).
Received: 12 October 2020 / Received in ﬁnal form: 4 August 2021 / Accepted:
20 August 2021
http://dx.doi.org/10.1097/MD.0000000000027169

1

Chen and Stanciu Medicine (2021) 100:36

Medicine

obtain the optimal parameter values for the decision variables A,
B, C, and D, we can use the optimized sinusoidal to derive a
contact function that will simulate the rate at which an infected
individual transmits the disease to other susceptible individuals.
The contact function shows how soon individuals in the
population can move between the susceptible, infectious, and
recovered groups. In particular, the contact (transmission) rate at
which a susceptible individual becomes infected can be obtained
by taking the ﬁrst derivative of0 Eq. (1) with respect to t. The
contact rate, denoted by bðtÞ ¼ f ðtÞ, is a cosinusoidal function of
time that informs the various rates of transmission during the
inﬂuenza season.

inﬂuenza data over multiple inﬂuenza seasons. To empirically
ground the model, we follow the literature and present a simpliﬁed,
yet accurate way of ﬁtting inﬂuenza seasonal transmission models
to publicly available data.[13,14] Using a system of differential
equations, we simulate the dynamics of the infection in the
population compartmentalized into several groups. The differential equations allow us to deﬁne the rates at which susceptible
individuals become infectious or infected individuals recover from
the disease. Lastly, we conduct an extensive sensitivity analysis to
validate our model by varying a wide range of common
experimental parameters discussed in the extant literature. This
study visualizes the progress of the inﬂuenza epidemic not only
when vaccine effectiveness wanes, but also when some seemingly
favorable change of conditions counter-intuitively contributes to a
worsening of the spread of inﬂuenza.
The remainder of this article is organized as follows: Section 2
presents the classic susceptible-infectious-recovered (SIR) model
that is often used for segmenting a population into groups during
an inﬂuenza epidemic. In Section 3, we conduct simulation
studies using various scenarios for investigating the implications
of the empirically based periodic transmission rate, waning
vaccination effectiveness, and viciousness of the inﬂuenza virus
on the size of the epidemic. Finally, in Section 4, we conclude with
a summary of our ﬁndings.

2.2. Epidemiological groups
Many studies have used differential equation-based simulation
models for simulating the course of inﬂuenza.[18–20] Typically,
these models place individuals in a predetermined number of
groups. In this study, we assume that, at any given time, each
individual in the population (N) belongs to one (and only one) of
the following groups: susceptible (S), vaccinated (V), infectious
(I), or recovered (R).[11,21–24] In particular, S includes those who
are healthy but exposed to the risk of contracting inﬂuenza from
any infectious individuals; V refers to the proportion of
individuals in N who are being vaccinated but who can also
continuously leak to group S; I denotes those who are infectious
agents of inﬂuenza to those in S; and R denotes those who have
contracted inﬂuenza, recovered, and are therefore immune for the
remainder of the season. Figure 1 exhibits a ﬂowchart that
conceptually illustrates to which group the individuals in a
population could belong during an inﬂuenza epidemic. Note that
the dotted line between V and S is the connection that has not yet
been considered in most of the inﬂuenza-related research so far.

2. Methods
In this section, we present an approach for ﬁtting a model to
inﬂuenza data. First, we deﬁne the groups that each individual in
a population will belong to during an inﬂuenza epidemic. Then,
using differential equations, we devise a deterministic epidemic
model to investigate the implications of varying model parameter
values on the severity of the inﬂuenza epidemic in the population.

2.3. Differential equations

2.1. Model design

Given the deﬁnition of the SVIR epidemic model, we developed a
system of deterministic differential equations that characterizes
the rates at which any individual in one group can move to
another group[25]:

Using a sinusoidal function for simulating inﬂuenza transmission
is not uncommon in epidemiological research.[15–17] For a given
empirical data set, we ﬁt the following sinusoidal function to the
weekly percentage of the positive laboratory specimens test
results over the course of a year:

f ðtÞ ¼ Asin


2p
þ D:
Bðt  CÞ

ð1Þ

where A speciﬁes the amplitude of the oscillation, B deﬁnes the time
horizon of a complete season, C determines the starting week in a
season, D shifts f(t) such that it is positive for all integers
t∈f1; 2; . . . ; 51; 52g, and t indexes the week number in a given year.
We then construct the following optimization problem to get
the ﬁtted parameter values for modeling the seasonal inﬂuenza
phenomenon:

Minimize

52
X
½xðtÞ  f ðtÞ2
t¼1

subject to A; B; C; D ≥ 0
B  52
f ðtÞ ≥ 0; 8t∈f1; 2; . . . ; 51; 52g:

ð2Þ

dSðtÞ
IðtÞ
¼ bðtÞSðtÞ
þ zVðtÞ
dt
N

ð3Þ

dVðtÞ
¼ zVðtÞ
dt

ð4Þ

dIðtÞ
ðIðtÞÞ
¼ bðtÞSðtÞ
 gIðtÞ
dt
N

ð5Þ

dRðtÞ
¼ gIðtÞ:
dt

ð6Þ

We use z to denotes the rate of the decreasing vaccine
effectiveness (i.e., waning effect). Studies showed that the vaccineinduced antibody titers can decrease, within a year after the
inoculation, to levels encountered in those without protection.[26]

We use x(t) to denote the weekly percentage of specimens with
positive results in any available historical data set. Once we
2
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laboratories often receive samples that have already tested
positive for an inﬂuenza virus at a clinical laboratory.[3]
Relatively speaking, the data from clinical laboratories are less
distorted than those from public health laboratories in terms of
truthfully representing the situations in the population. Therefore, we chose to use data from four inﬂuenza seasons, starting
with the 2015 to 2016 season, to inform the estimates for our
epidemiological model. Figure 2 displays the time-series data of
four (over-imposed) inﬂuenza seasons consisting of 208 (52  4)
weekly fractions of the positive laboratory specimens test results.
Overall, the percentages rise rather quickly at the beginning of the
season before declining to some low levels starting with week 24.
Note that every plot has peaks between week 52 and week 12 and
a small uptick before the end of the season, at around week 36.
Because we use only deidentiﬁed statistical data aggregated by
the CDC at the national level on a weekly basis, no information
can be used to uniquely identify each individual. Thus, this study
does not involve human subjects in a way that would require
review or approval by Bucknell University’s Institutional Review
Board.

Figure 1. Flowchart of the SVIR model for simulating an inﬂuenza epidemic.

Another biological deﬁnition of the waning effect is that the
antigens on the inﬂuenza virion surface (i.e., the target of
protective immunity) continually evolves and mutates in the
human population. Hence, the inﬂuenza strain increasingly
differs from its progenitor so that the vaccine-induced immunity
against the progenitor can diminish over time.[27] Mathematically, we assume some percent of the vaccinated group can lose the
immunity protection and rejoin to the susceptible group.
Additionally, g denotes the inverse of the average length of time
an individual stays infectious until moving to the R group. For
example, if infected individuals take, on average, four days to
recover, then g ¼ 0:25. To solve the differential equations, we
need the following initial conditions:
Sðt0 Þ
Vðt0 Þ
Iðt 0 Þ
Rðt 0 Þ

¼
¼
¼
¼

3.2. Model ﬁtting
As opposed to directly imposing some function for the inﬂuenza
contact (transmission) rate,[20] we derive the cosinusoidal contact
rate from the empirical data. To this end, we solved the
minimization problem in Eq. (2) using MATLAB to obtain A, B,
C, and D and specify Eq. (1) (solver sequential quadratic
programming; www.mathworks.com). In the deﬁnition of x(t) in
Eq. (2), we use the average of the percentages in Figure 2, that is,
52 weekly average ratios across the four inﬂuenza seasons. (e.g., x
(1) is the average of the four ﬁrst-week percentages from the data
sets.) For the given empirical data set, we ﬁt the sinusoidal
function (1), using the model speciﬁed in (2) and the parameters x
(t) as deﬁned above. The optimized parameter values of A, B, C,
and
and 9.3964, respectively
 2 D are 9.4215, 43.0102, 139.2729,

R ¼ 0:8992; RMSE ¼ 2:4671 . Figure 3 compares the average
weekly percent of positivity tests with Eq. (1) given the ﬁtted
values of the parameters.

ð 1  a Þ ð N  I0 Þ
aðN  I0 Þ
I0
0:

where t0 denotes the time when the pathogen is introduced in the
population, and a represents the level of population immunity
given the vaccine’s effectiveness and the proportion of susceptible
individuals being vaccinated.
Admittedly, some more advanced, complex inﬂuenza transmission models with additional parameters will be able to better
capture other temporal or systematic variations in the time series
data. For example, while the differential equations are popular in
simulating the course of inﬂuenza transmission, they tend to
focus more on modeling the behavior of the groups as a whole. To
focus on modeling the probability of individuals being infected
given their demographic or community information, agent-based
models are capable of considering the stochastic nature of the
transmission rate between individuals.[11,24] For more discussions on the differential equations and the agent-based simulation
models, see Paleshi et al[12] Our parsimonious mathematical
models and differential equations are meant for capturing the
main patterns that are evident in the empirical data for the
following numerical study.

30

National influenza results reported to CDC
'15-'16 Data
'16-'17 Data
'17-'18 Data
'18-'19 Data

Percent of positive tests

25

3. Results
3.1. Empirical data
From the various publicly available data sets on the CDC’s
website, we focus on the weekly percentage of the positive
laboratory specimens test results and use those as a proxy for the
fraction of the population that is infected. The data were collected
from ∼300 clinical laboratories located throughout all 50 states,
Puerto Rico, Guam, and the District of Columbia. Prior to the
2015 to 2016 inﬂuenza season, the weekly inﬂuenza update from
public health and clinical laboratories were not separately
reported. Compared to the clinical laboratories, public health

20

15
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5

0
40

52

12

24

36

Week of the year
Figure 2. Seasonality of annual incidence of inﬂuenza, 2015 to 2019.
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observe the duration of the infectious period. The authors
reviewed the literature and found that the 95% probability
intervals of the mean duration of the infectious period can be any
number of days up to 12 days, while the majority of cases having
an infectious period are shorter than 2.9 days. Thus, we consider
1
g, the recovery rate of infected individuals, to vary between 12
and
1
.
Since
it
is
of
interest,
we
also
tracked
and
observed
during
our
2
simulations the total number of recovered individuals, as a proxy
for the size of the epidemic.
Another uncertainty that we bring into the study is the
proportion of people who gain immunity, at least in the beginning
of the season. Statistics from the 2018 inﬂuenza season showed
that, depending on age group, the percentage of people who
received an inﬂuenza vaccination varies between 30% and 70%,
with vaccine effectiveness ranging from 10% to 60%.[29,30] Thus,
we let a, the proportion of susceptible individuals fully protected
by the vaccine, vary between 3% and 42%. Moreover, we vary
I0 , the initial number of infected individuals, between 1 and 100.
Lastly, Grohskopf et al[31] pointed out that the observed waning
effect might not consistently manifest itself across all age groups,
virus subtypes, or seasons. Nonetheless, Ferdinands et al[32]
examined the association between inﬂuenza vaccine effectiveness
and time since vaccination among patients in the United States.
The authors found signiﬁcant evidence that inﬂuenza vaccine
protection could decline by 6% to 11% per month since the time
of vaccination, depending on inﬂuenza type. Thus, we vary z, the
rate at which the number of (newly) vaccinated individuals
decreases over time, from 6% to 11%.

Next, we derive the estimated contact rate function at which a
susceptible individual becomes infected when contacting an
infectious individual. Intuitively, the contact rate determines the
instantaneous rate of change to the weekly positivity rate. We
propose a novel approach for ﬁnding the contact rate by
borrowing a fundamental concept from Physics: the contact rate
is to the weekly positivity rate as the acceleration is to velocity.
That is, if we view the positivity rate in a week as velocity, then
the contact rate should be the instantaneous rate of acceleration
in the given week. Thus, we take the ﬁrst derivative of the sine
function f(t) with respect to t to ﬁnd the contact rate as a cosine
function:

^ ¼ 1:3764 cos
bðtÞ


2p
ðt  139:2729Þ þ 1 :
43:0102

ð7Þ

As such, the contact function Eq. (7) has a maximum at week 2
(in January) and a minimum at week 24 (in June) for a given year,
matching the empirical observation that inﬂuenza activity often
begins in October, peaks sometime between December and
February, and lasts as late as May.[3] Note that the constant 1 in
^ realistic for all integer
Eq. (7) is added to keep the function bðtÞ
t∈f1; 2; . . . ; 51; 52g. Without the added constant, Eq. (7)
oscillates between +1.3764 and 1.3764 over t. If adding any
constant <1, then Eq. (7) might render some negative contact
rate. If the added constant is >1, then Eq. (7) might render some
increasing infection rate for the population even during the
summertime.

3.4. Numerical experiments
3.3. Experiment parameters

We code the system of differential Eqs. (3) to (6) in MATLAB and
solve them numerically for the values of a given t under different
scenarios (solver ode45; www.mathworks.com). When computing, we begin by assigning the initial values of the groups of the
population, with N and R0 being always held constant at 106 and
at 0, respectively. In addition, every inﬂuenza season spans 52
weeks, starting at week 40 of 1 year and ending at week 39 of the
following year. During the season, individuals continuously
interact with each other, and the size of the four groups changes
at the rates deﬁned by the differential equations.
Figure 4 shows the impact of the recovery rate on the
number of individuals in the four groups over the course of
the inﬂuenza season. We observe that an inﬂuenza virus that
requires a longer recovery time tends to cause the population to
experience another uptick in the number of infected individuals at
around week 36. We also note that the longer the time the
infected individuals take to recover, the larger the epidemic size
is—that is, the total number of recovered individuals at the end
of the season.
Figure 5 shows that if the population has a larger number of
initially infected individuals (I), then the peak of the season would
not only arrive sooner but also be smaller. A subtle and counterintuitive observation is that the epidemic size—that is, the total
number of recovered individuals at the end of the season—is
actually smaller when I is larger. We will examine this
phenomenon in more detail shortly.
Figure 6 shows the impact of the proportion of the vaccinated
population on the number of individuals in the four groups over
the course of the inﬂuenza season. The greater the proportion of
individuals receiving the vaccination at the beginning of the
season, the smaller the epidemic size (the total number of

This study also examines the impact of the length of the infectious
period on the size of the epidemic. According to CDC,[3] infected
people can be contagious one day before experiencing symptoms,
which typically last 3 to 7 days, and can stay contagious for up to
7 days after becoming sick. The contagious period can be longer
than 7 days for children and some people with weakened immune
systems. Cori et al[28] pointed out that it is impossible to directly

25
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Percent of positive tests
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Figure 3. Performance of ﬁtted model vs actual weekly data.
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Figure 4. Evolution of the SVIR groups as a function of the recovery rate.

recovered individuals) at the end of the season. An increase in a
seems to lead to a decrease in the size of the epidemic, but it also
delays the peak of the season, as well as leading to an uptick in
infected individuals toward the end of the season.
Figure 7 highlights the missing link in the literature—the effect
of the individuals leaking from V to S when the vaccination is
subject to the waning effect. Even with a slight increase in the
waning effect, for example, z from 0 to 6% (i.e., top-left panel to
top-right panel), the size of the epidemic could increase by more
than 100%. Therefore, researchers studying related topics should
not disregard the waning effect. Although a higher waning rate
leads to a larger epidemic size, the peak of the season takes place
roughly in the same week. The implication is that researchers or
practitioners may not be able to tell if the effectiveness of a given
vaccine can wane over time by observing the timing of the peak of
the season.
Figure 8 shows the epidemic size given four different values for
the number of initially infected individuals. Counter-intuitively,
relatively faster recovery rates, roughly between 1/12 and 1/7, can
actually make the epidemic worse. Another interesting observa-

tion is that, for the cases where the recovery rate is greater than
about 15%, the greater the number of initially infected
individuals, the smaller the epidemic (i.e., the smaller the total
number of recovered individuals at the end of the season). Note
that for inﬂuenza that entails a recovery period of 7 days or fewer,
a greater number of initially infected individuals can lead to a
decrease in the season’s epidemic size. But for inﬂuenza that
entails a recovery period of 7 days or more, a greater number of
initially infected individuals can lead to an increase in the season’s
epidemic size.
Figure 9 illustrates that the higher the waning rate, the larger
the epidemic size. The implication is that the effectiveness of the
vaccine must be made as good as possible to effectively mitigate
the potential outbreak of an epidemic. Similar to the phenomenon observed in Figure 8, a faster recovery rate might increase the
epidemic size, and the phenomenon holds even under different
rates of the waning effect.
To conduct a sensitivity analysis, we separately ﬁtted the
models using the data of the individual seasons and obtained four
different sets of values of the parameters A, B, C, and D as shown
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Figure 5. Evolution of the SVIR groups as a function of the size of the initial infected population.
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Figure 6. Evolution of the SVIR groups as a function of the proportion of the vaccinated population.

year.[24] In this study, we combined multiple approaches to better
capture the complexities of the inﬂuenza epidemic phenomenon.
The theoretical contribution of our study lies in ﬁtting empirical
inﬂuenza data to the models that capture the periodic phenomena
of inﬂuenza infections and the oscillating contact rate over time.
Moreover, we extended the classic SIR model to the SVIR model
by incorporating the effect of waning vaccination immunity to
better reﬂect the course and spread of inﬂuenza infections. The

in Table 1. Not reported here, all of the results using the
parameter values led to the same conclusions as do those using
the average of the four seasons’ data.

4. Discussion
Inﬂuenza has been a leading cause of death in the United States.
Despite vaccination, the number of susceptible, infected, and
recovered individuals seems to follow similar patterns year after
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Figure 7. Evolution of the SVIR groups as a function of the unwaning vaccination immunity.
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Table 1
Distribution of ﬁtted model parameter values.

9.9

Data
A
B
C
D

9.85

9.8

9.7

9.65
0.15

0.2

0.25

’16-‘17

’17-‘18

’18-‘19

7.7053
37.7859
128.3949
7.6902

9.5389
42.7578
138.8957
9.5291

10.8499
45.6792
144.3897
10.8344

10.3989
42.0445
136.6177
10.3988

with each other, and as likely to get or spread the disease, which
may not be true for populations that are sparsely connected.
Nevertheless, the numerical experiments present a number of
interesting phenomena that are worth pursuing further.
Future research and extensions of the investigations in this
study can consider different types of inﬂuenza viruses. According
to CDC,[3] both type A and type B inﬂuenza viruses are
responsible for causing seasonal epidemics of the disease every
winter.[10] It has been reported that different types of the
inﬂuenza virus could show up at different times in an inﬂuenza
season.[33] Thus, the implications of the waning effect over time
we discussed in this study may pan out differently for different
types of the inﬂuenza virus. Another direction for future research
is to consider the group of immunosuppressed individuals in the
model.[34] Individuals with immune dysfunction may not respond
to the vaccine as well as people without immune dysfunction.[35]
Furthermore, people who are severely immunocompromised
(e.g., HIV-infected people, organ transplant recipients, or people
who undergo immunosuppressive treatments) tend to prolong
inﬂuenza virus shedding, increase morbidity or mortality
following infection, and be reinfected with the same virus
strain.[36,37] Thus, researchers can study the impact of immunosuppression on the SVIR model. Finally, researchers may
consider applying the framework of this study and analyze
inﬂuenza data from other countries or regions, for additional
insights.
As the entire world is increasingly inoculated with COVID-19
vaccines, we anticipate that many more studies will be underway
to further model the immunity provided by the vaccines. The
waning effect we consider in this article, even though introduced
in the context of an inﬂuenza epidemic, could become especially
relevant in modeling and understanding the COVID-19 pandemic immunity-related parameters. At the same time, the
reliability and the frequency of data reporting will have a
direct effect on gaining a better understanding of vaccine
administration.
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Figure 8. Faster recovery rate does not necessarily reduce the epidemic size,
regardless of the number of initially infected individuals.

practical implication of the study lies in simulating the size of the
inﬂuenza epidemic when varying several model parameters. In
particular, we show how an uptick in inﬂuenza cases toward the
end of the season or even a delay in the peak of the season might
be caused by scenarios involving an inﬂuenza virus that entails a
longer recovery time, or when a greater portion of the population
gets vaccinated. The rather counter-intuitive results suggest that a
larger number of initially infected individuals might not only
bring the inﬂuenza season to an end sooner but also reduce the
size of the epidemic. Moreover, an inﬂuenza virus that entails
a faster recovery rate does not necessarily lead to a smaller
epidemic size.
One limitation of the study may be attributed to the availability
of the less distorted data we chose to use, which was unavailable
on the CDC website until 2015. In addition, the differential
equation model assumes that all subjects are directly connected
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